+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury



Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury



Coronary Artery Disease 22(1): 87-91



To investigate the effects of loading dose of atorvastatin on periprocedural myocardial injury and inflammatory reaction in patients with non-ST segment elevation (NSTE) acute coronary syndromes (unstable angina or NSTE acute myocardial infarction). A total of 81 patients with NSTE-acute coronary syndromes were randomly divided into the pretreatment with atorvastatin group [80 mg 12 h before percutaneous coronary intervention (PCI), with a further 40 mg preprocedure dose] (n=41) or the placebo group (n=40). The main end point was a 30-day incidence of major adverse cardiac events (cardiac death, nonfatal acute myocardial infarction, or revascularization with either PCI or coronary artery bypass grafting). Creatine kinase-MB, cardiac troponin I, and high-sensitivity C-reactive protein levels were measured at the baseline and at 8 and 24 h after the procedure. Major adverse cardiac events occurred in 2.4% of patients in the atorvastatin group and 22.5% of those in the placebo group (P=0.0161). This difference was mostly because of reduction in the incidence of myocardial infarction (2.4 vs. 20.0%; P=0.0307). Markers of the two groups were elevated after PCI; however, the higher values of creatine kinase-MB, cardiac troponin I, and high-sensitivity C-reactive protein in the atorvastatin treatment group were significantly lower than those in the placebo group (P<0.01). Short-term pretreatment with a high dose of atorvastatin significantly reduces procedural myocardial injury in early PCI.

(PDF emailed within 0-6 h: $19.90)

Accession: 052873992

Download citation: RISBibTeXText

PMID: 21169815

DOI: 10.1097/MCA.0b013e328341baee


Related references

Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?. Current Medical Research and Opinion 30(3): 381-386, 2014

Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study. Clinical Therapeutics 35(3): 261-272, 2013

Effects of First High-Dose Atorvastatin Loading in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Therapeutics 25(3): E291-E298, 2016

The Effect of High Dose Cilostazol and Rosuvastatin on Periprocedural Myocardial Injury in Patients with Elective Percutaneous Coronary Intervention. Acta Cardiologica Sinica 31(4): 292-300, 2016

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. Jacc. Cardiovascular Interventions 3(3): 332-339, 2010

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20(6): 319-324, 2013

Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention. Coronary Artery Disease 26(8): 671-677, 2016

Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. American Journal of Cardiology 104(5): 630-633, 2009

Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 93(6): 703-707, 2007

Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention from the ARMYDA-CIN Atorvastatin for Reduction of MYocardial Damage during An. 2011

Comparison of the efficacy of periprocedural rosuvastatin versus atorvastatin treatment in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal 34(Suppl 1): 24-24, 2013

Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST-segment elevation myocardial infarction. Experimental and Therapeutic Medicine 7(2): 316-322, 2014

Prevention of Periprocedural Myocardial Injury During Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Circulation Journal 82(7): 1746-1748, 2018

Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. International Journal of Cardiology 168(3): 2494-2497, 2014

Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?. Heart 96(10): 736-740, 2011